Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
Neutropenia Biologic Drug Treatment Industry Expansion: How the Market Size Has Grown Over the Last 5 Years?
The market for biologic drug treatment of neutropenia has seen robust growth in the past years. Its size is projected to increase from $13.22 billion in 2024 to $14.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.5%. Factors such as accessibility and reimbursement of the market, patient advocacy and awareness, education and training of physicians, development of biologic drugs, and successful clinical trials contributed to the growth during the historic period.
The market size of biologic drug treatments for neutropenia is predicted to experience a significant increase within the upcoming years. It is projected to expand to $18.1 billion by 2029, with a CAGR of 6.5%. This anticipated growth during the forecast period can be linked to factors such as healthcare cost management, the establishment of patient-oriented care systems, the progression of combination therapies, regulatory shifts, and the acceptance of personalized medicine strategies. Key trends to watch during the forecast period are improved global market access, enhancement in manufacturing procedures, the refinement of treatment protocols, the adoption of biosimilars, and the creation of long-acting formulations.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What Growth Drivers Are Responsible for Accelerating Neutropenia Biologic Drug Treatment Market Growth?
The global increase in cancer cases is expected to propel the neutropenia biologic drug market’s growth. The escalating incidence of cancer, combined with more people opting for chemotherapy, has meant a rise in the number of individuals afflicted with neutropenia. For instance, the American Cancer Society predicts that in January 2022, there will be approximately 1.9 million fresh cancer diagnoses and 609,360 cancer-related deaths in the US, equating to about 1,670 deaths every day.
Lung, prostate, bowel, and female breast cancer are the four most prevalent cancer types globally, comprising 43 percent of all new cancer diagnoses. Consequently, the global increase in cancer rates is expected to stimulate demand for the neutropenia biologic drug treatment market in the coming years.
Performance of Leading Segments in the Neutropenia Biologic Drug Treatment Global Market
The neutropenia biologic drug treatment market covered in this report is segmented –
1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim
2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
Subsegments:
1) By Filgrastim: Brand Name Examples: Neupogen, Indications And Usage
2) By Pegfilgrastim: Brand Name Examples: Neulasta, Indications And Usage
3) By Lenograstim: Brand Name Examples: Granocyte, Indications And Usage
4) By Lipegfilgrastim: Brand Name Examples: Lonquex, Indications And Usage
5) By Sargramostim: Brand Name Examples: Leukine, Indications And Usage
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
What are the upcoming Trends Poised to Transform the Future of the Neutropenia Biologic Drug Treatment Market?
Leading firms in the neutropenia biologic drug treatment sphere are innovating biosimilars, aiming to provide more economical alternatives to existing biologics. Biosimilars are biological drugs intended to be almost identical to an already authoritatively approved biologic, demonstrating no noticeable disparities in safety or efficacy. For example, in May 2023, Amneal Pharmaceuticals, an American pharmaceutical organization, introduced Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, designed to treat and prevent febrile neutropenia in patients receiving chemotherapy. It engages with specific receptors on hematopoietic cells, triggering the growth and differentiation of bone marrow neutrophil precursors. Such action magnifies the neutrophil generation, critical in combating infections, particularly in patients receiving myelosuppressive chemotherapy. This, in turn, curtails the appearance of febrile neutropenia linked with cancer therapies.
What Are the Regional Hotspots for Neutropenia Biologic Drug Treatment Market Growth?
The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
Which Companies Hold the Largest Market Share in the Neutropenia Biologic Drug Treatment Industry?
Major companies operating in the neutropenia biologic drug treatment market include Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Celgene Corporation, Biogen Inc., AbbVie Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Gilead Sciences Inc., Daiichi Sankyo Company, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy’s Laboratories Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…px?id=3456
How Our Market Research Reports Help Maximize ROI Across Industries:
*Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
*Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
*Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
